US Patent
US8969336 — Diamino heterocyclic carboxamide compound
Composition of Matter · Assigned to Kotobuki Seiyaku Co Ltd · Expires 2032-11-28 · 7y remaining
Vulnerability score
4/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects a class of diamino heterocyclic carboxamide compounds that inhibit the kinase activity of the EML4-ALK fusion protein.
USPTO Abstract
Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.